This company has been acquired
Lumos Pharma Future Growth
Future criteria checks 0/6
Lumos Pharma's revenue and earnings are forecast to decline at 1.8% and 11.6% per annum respectively while EPS is expected to grow by 41.3% per annum.
Key information
-11.6%
Earnings growth rate
41.3%
EPS growth rate
| Biotechs earnings growth | 28.2% |
| Revenue growth rate | -1.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate
May 23
We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate
Aug 25Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?
Mar 13Lumos Pharma announces new buyback program
Aug 16Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation
Mar 22Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth
Nov 04What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?
Dec 09Lumos Pharma (LUMO) Investor Presentation - Slideshow
Nov 17Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | -51 | N/A | -49 | 3 |
| 12/31/2025 | 1 | -43 | N/A | -41 | 4 |
| 12/31/2024 | 6 | -30 | N/A | -34 | 4 |
| 9/30/2024 | 2 | -35 | -32 | -32 | N/A |
| 6/30/2024 | 1 | -36 | -34 | -34 | N/A |
| 3/31/2024 | 2 | -37 | -35 | -35 | N/A |
| 12/31/2023 | 2 | -34 | -31 | -31 | N/A |
| 9/30/2023 | 2 | -33 | -30 | -30 | N/A |
| 6/30/2023 | 2 | -32 | -27 | -27 | N/A |
| 3/31/2023 | 2 | -31 | -28 | -28 | N/A |
| 12/31/2022 | 2 | -31 | -27 | -27 | N/A |
| 9/30/2022 | 1 | -28 | -27 | -27 | N/A |
| 6/30/2022 | 1 | -29 | -28 | -28 | N/A |
| 3/31/2022 | 0 | -30 | -27 | -27 | N/A |
| 12/31/2021 | 0 | -30 | -30 | -30 | N/A |
| 9/30/2021 | 0 | -27 | -31 | -31 | N/A |
| 6/30/2021 | 0 | -18 | -23 | -23 | N/A |
| 3/31/2021 | 0 | -15 | -30 | -30 | N/A |
| 12/31/2020 | 0 | -6 | -23 | -23 | N/A |
| 9/30/2020 | 0 | -7 | -19 | -19 | N/A |
| 6/30/2020 | 0 | -12 | -21 | -21 | N/A |
| 3/31/2020 | 0 | -10 | -10 | -10 | N/A |
| 12/31/2019 | N/A | -13 | -9 | -9 | N/A |
| 9/30/2019 | N/A | -11 | -8 | -8 | N/A |
| 12/31/2018 | N/A | -11 | -11 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LUMO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LUMO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LUMO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LUMO's revenue is expected to decline over the next 3 years (-1.8% per year).
High Growth Revenue: LUMO's revenue is forecast to decline over the next 3 years (-1.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LUMO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/13 01:43 |
| End of Day Share Price | 2024/12/11 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lumos Pharma, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Eun Kyung Yang | Jefferies LLC |
| Elemer Piros | Roth Capital Partners |